Senior appointments for Takeda’s Europe and Canada team
pharmafile | July 18, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Takeda
Takeda Pharmaceuticals has appointed David Milton as head of Marketing & Product Portfolio Strategy, and Dr Nizamul Islam as head of Medical Affairs in its Europe and Canada region.
Since 2009 Milton has been vice president, Marketing & Commercial Effectiveness where he was responsible for leading certain commercial operations including the introduction of a new commercial cross functional team model for product launches.
Prior to working at Takeda Milton spent eight years at Shire where he rose to senior vice president of the renal business unit, with full accountability and line management responsibility for sales, marketing, R&D, finance, product manufacture and supply worldwide.
Dr Islam also joined Takeda in 2009 and was, most recently, medical affairs therapy lead for urology, the central nervous system and gastro-intestinal medicine where he showed strategic medical project leadership experience managing internal cross-functional teams. In his new role he will be the medical affairs lead across all therapy areas for the Europe and Canada region.
Before joining Takeda, Islam was a global medical director for Pfizer based in New York, and involved in the global medical affairs support for major brands within the speciality therapy area focusing on pharmacotherapies in Neurology, Urology and Respiratory Medicine.
Both Milton and Islam will be based in Switzerland in their new roles.
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
